アブストラクト
| Title | 2. 男性骨粗鬆症の治療 - デノスマブ, テリパラチド, ロモソズマブ - |
|---|---|
| Subtitle | 特集 男性骨粗鬆症II III. 治療 |
| Authors | 萩野浩 |
| Authors (kana) | |
| Organization | (教授, 部長) / 鳥取大学医学部保健学科, リハビリテーション部 |
| Journal | THE BONE |
| Volume | 33 |
| Number | 3 |
| Page | 317-321 |
| Year/Month | 2020 / 2 |
| Article | 報告 |
| Publisher | メディカルレビュー社 |
| Abstract | 男性の骨折例は女性例よりも生命予後が悪いことが知られており, 男性骨粗鬆症の治療は重要である. 男性骨粗鬆症を対象とした臨床試験は少ないが, デノスマブ, テリパラチド, ロモソズマブによる治療で骨密度増加が確認されている. 骨折抑制を示した報告は少ないが, 骨密度増加の結果からこれらの薬剤の男性骨粗鬆症での治療効果は, 閉経後骨粗鬆症と同等と考えられている. |
| Practice | 臨床医学：外科系 |
| Keywords | 男性骨粗鬆症 (male osteopor osis), デノスマブ (denosumab), テリパラチド (teriparatide), ロモソズマブ (romosozumab) |
- 全文ダウンロード： 従量制、基本料金制の方共に913円(税込) です。
参考文献
- 1) Hagino H, Furukawa K, Fujiwara S, et al. Recent trends in the incidence and lifetime risk of hip fracture in Tottori, Japan. Osteoporos Int. 2009;20:543-8.
- 2) Cummings SR, Martin JS, McClung MR, et al. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. The New England journal of medicine. 2009;20:756-65.
- 3) Orwoll E, Teglbjaerg CS, Langdahl BL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012;97:3161-9.
- 4) Langdahl BL, Teglbjaerg CS, Ho PR, et al. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab. 2015;100:1335-42
- 5) Smith MR, Egerdie B, Toriz NH, et al. Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer, The New England journal of medicine. 2009.
残りの11件を表示する
- 6) Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone(1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-41.
- 7) Nakamura T, Sugimoto T, Nakano T, et al. Randomized Teriparatide [human parathyroid hormone(PTH)1-34] Once-Weekly Efficacy Research(TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab. 2012;97:3097-106.
- 8) Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 2000;85:3069-76.
- 9) Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone(1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18:9-17.
- 10) Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005;16:510-6.
- 11) Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349:1216-26.
- 12) Leder BZ, Neer RM, Wyland JJ, et al. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab. 2009;94:2915-21.
- 13) Ishibashi H, Crittenden DB, Miyauchi A, et al. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study. Bone. 2017;103:209-15.
- 14) Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. The New England journal of medicine, 2016;375:1532-43.
- 15) Saag KG, Petersen J, Brandi ML, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. The New England journal of medicine. 2017;377:1417-27.
- 16) Lewiecki EM, Blicharski T, Goemaere S, et al. A Phase 3 Randomized Placebo-controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab. 2018;103:3183-93.
